Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Gross Margin (2019 - 2026)

Catalyst Pharmaceuticals filings provide 8 years of Gross Margin readings, the most recent being 90.31% for Q1 2026.

  • On a quarterly basis, Gross Margin rose 298.0% to 90.31% in Q1 2026 year-over-year; TTM through Mar 2026 was 85.96%, a 16.0% decrease, with the full-year FY2025 number at 85.19%, down 81.0% from a year prior.
  • Gross Margin hit 90.31% in Q1 2026 for Catalyst Pharmaceuticals, up from 82.91% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 90.31% in Q1 2026 to a low of 81.57% in Q4 2022.
  • Median Gross Margin over the past 5 years was 85.94% (2025), compared with a mean of 85.91%.
  • Biggest five-year swings in Gross Margin: plummeted -211bps in 2022 and later soared 413bps in 2023.
  • Catalyst Pharmaceuticals' Gross Margin stood at 81.57% in 2022, then grew by 5bps to 85.7% in 2023, then fell by -1bps to 84.74% in 2024, then dropped by -2bps to 82.91% in 2025, then rose by 9bps to 90.31% in 2026.
  • The last three reported values for Gross Margin were 90.31% (Q1 2026), 82.91% (Q4 2025), and 84.73% (Q3 2025) per Business Quant data.